‫شركة Axi تطلق أكبر مسابقة تداول عالمية لها على الإطلاق، مع جوائز تصل الى 250 ألف دولار أمريكي

ستضم مسابقة التداول 49 فائزًا بما في ذلك الجائزة الكبرى التي تبلغ قيمتها 100,000 دولار أمريكي

SYDNEY, Australia, June 17, 2024 (GLOBE NEWSWIRE) — لقد أطلقت شركة Axi الرائدة كوسيط لتداول العملات الأجنبية والعقود مقابل الفروقات عبر الإنترنت، أكبر مسابقة تداول عالمية لعام 2024، بمجموع جوائز إجمالي قدره 250,000 دولار أمريكي.

ترفع شركة Axi مستوى التحدي وتدعو جميع المتداولين إلى اظهار مهاراتهم والفوز بجوائز ضخمة، بما في ذلك الجائزة الكبرى التي تبلغ قيمتها 100,000 دولار أمريكي. سيتم منح أكثر من 45 جائزة للعائد على الاستثمار، وأعلى حجم تداول، وأفضل عائد على الاستثمار لكل أسبوع، بالإضافة إلى خمس جوائز عن طريق السحب بقيمة 500 دولار أمريكي أسبوعيًا.

لقد تم فتح باب التسجيل للمسابقة، ومن المقرر أن تستمر المسابقة لمدة أربعة أسابيع من 3 إلى 30 يونيو. وفقًا لشركة Axi، فإن المسابقة مفتوحة للعملاء الجدد أو الحاليين، ويجب على المتداولين الطموحين المهتمين بالمشاركة ان يكن لديهم حساب تداول حقيقي مع الشركة او يقوموا بفتح حساب تداول حقيقي جديد، وإيداع ما لا يقل عن 200 دولار، وتداول على الأقل 1 عقد (لوت).

يشارك لويس كوبر، الرئيس التنفيذي للشؤون التجارية في شركة Axi، حماسه للمسابقة القادمة قائلا: “”Trade Your Edge” هو شعارنا، وفي شهر يونيو ندعو المتداولين لدينا للقيام بذلك – التداول بمهاراتهم في أسواقهم المفضلة مثل سوق تداول العملات الأجنبية والذهب والعملات الرقمية، للحصول على فرصة للفوز بجوائز نقدية مذهلة، بما في ذلك الجائزة الكبرى التي تبلغ قيمتها 100,000 دولار أمريكي.”

لقد كانت هذه سنة مالية ناجحة للغاية بالنسبة للوسيط؛ فقد قدموا مؤخرًا برامج جديدة متطورة وقاموا أيضًا بتوسيع محفظة شراكاتهم لتشمل نادي Man City Women ونادي LaLiga Girona FC وجون ستونز، اللاعب الدولي الإنجليزي والفائز بالدوري الإنجليزي الممتاز ست مرات، كسفير للعلامة التجارية للشركة.

لمعرفة المزيد عن المسابقة وطريقة التسجيل، قم بزيارة:

https://www.axi.com/int/promotions/global-trading-competition

عن شركة Axi

شركة Axi هي شركة وساطة عالمية لتداول العملات الأجنبية والعقود مقابل الفروقات عبر الإنترنت. باعتبارنا الوسيط المفضل لآلاف العملاء الطموحين في أكثر من 100 دولة حول العالم، فإننا نساعد جميع أنواع المتداولين وشركات التداول والبنوك والمؤسسات المالية في العثور على الميزة التنافسية التي يحتاجونها لتحقيق أهدافهم المالية من خلال المعاملات المستنيرة التي تتم في الأسواق المالية العالمية. تقدم شركة Axi مجموعة شاملة من الأصول بما في ذلك العقود مقابل الفروقات للعديد من فئات الأصول مثل تداول العملات الأجنبية والأسهم والنفط والمعادن الثمينة والقهوة والمؤشرات والسلع الأخرى.

في شركة Axi، نحن نفخر بسمعتنا كوسيط صادق وعادل ومسؤول. تشهد جوائزنا العالمية العديدة وتقييماتنا على الثقة التي اكتسبناها من عملائنا الذين يقدرون خدمتنا الاستثنائية والتنفيذ السريع والمدفوعات الآمنة والسحب السهل. بالإضافة إلى ذلك، فإننا نعمل بشكل فعال مع السلطات التنظيمية الحاكمة في جميع أنحاء العالم لضمان تجاوزنا لأعلى معايير الصناعة.

مسابقة التداول متاحة فقط لعملاء شركة AxiTrader Limited. تحمل العقود مقابل الفروقات (CFDs) مخاطر عالية لخسارة الاستثمار. غير متاح للمقيمين في استراليا ونيوزيلندا والاتحاد الأوروبي والمملكة المتحدة. تطبق الشروط والأحكام.

لمزيد من المعلومات أو التعليقات الإضافية من شركة Axi، يرجى التواصل معنا عبر: [email protected]

GlobeNewswire Distribution ID 1000966691

Axi lança sua maior competição global de trading, com prêmios de $250,000 USD

A competição de trading terá 49 vencedores, incluindo um grande prêmio de $100,000 USD

SYDNEY, Australia, June 17, 2024 (GLOBE NEWSWIRE) — A principal corretora online de FX e CFD, Axi, lançou a maior competição global de trading de 2024, com um total de prêmios de $250,000 USD.

A Axi está agitando o mercado, convidando traders de todos os tamanhos a operarem seu melhor e ganharem mega prêmios, incluindo o grande prêmio de $100,000 USD. Mais de 45 prêmios serão distribuídos para ROI, maior volume de trading, melhor ROI de cada semana, além de cinco prêmios aleatórios de $500 USD por semana.

As inscrições para a competição já começaram, e a competição de quatro semanas ocorrerá de 3 a 30 de junho. Segundo a corretora, a competição está aberta tanto para novos clientes quanto para clientes existentes, e traders ambiciosos interessados em participar devem abrir ou já possuir uma conta real de trading na Axi, depositar um mínimo de $200 e operar pelo menos 1 lote.

Louis Cooper, Diretor Comercial da Axi, compartilha sua empolgação para a próxima competição: “’Opere seu melhor’ é nosso lema, e em junho convidamos nossos traders a fazer exatamente isso – operar seu melhor em seus mercados favoritos, como Forex, Ouro, Cripto, para ter a chance de ganhar prêmios em dinheiro incríveis, incluindo o prêmio máximo de $100,000 USD.”

Este foi um ano financeiro muito bem-sucedido para a corretora; eles recentemente introduziram novos programas inovadores e também expandiram seu portfólio de parcerias para incluir o time feminino do Man City, o clube da LaLiga Girona FC, e o inglês e seis vezes vencedor da Premier League, John Stones, como embaixador da marca da empresa.

Para saber mais sobre a competição e se inscrever, visite:

https://www.axi.com/int/promotions/global-trading-competition

Sobre a Axi

A Axi é uma corretora global online de FX e CFDs. Uma corretora preferida por milhares de clientes ambiciosos em mais de 100 países ao redor do mundo, ajudamos todos os tipos de traders, empresas de trading, bancos e organizações financeiras a encontrar a vantagem de que precisam para alcançar seus objetivos financeiros por meio de transações informadas realizadas nos mercados financeiros mundiais. A Axi oferece uma ampla gama de ativos, incluindo CFDs para várias classes de ativos, como Forex, Ações, Petróleo, Metais Preciosos, Café, Índices e outras commodities.

Na Axi, temos orgulho de nossa reputação como uma corretora honesta, justo e responsável. Nossos numerosos prêmios globais e avaliações atestam a confiança e a credibilidade que conquistamos de nossos clientes, que valorizam nosso serviço excepcional, execução rápida, pagamentos seguros e retiradas fáceis. Da mesma forma, também trabalhamos proativamente com autoridades reguladoras líderes em todo o mundo para garantir que superamos os mais altos padrões da indústria.

A competição de trading está disponível apenas para clientes da AxiTrader Limited. CFDs carregam um alto risco de perda de investimento. Não disponível para residentes de AU, NZ, UE e Reino Unido. Aplicam-se termos e condições.

Para mais informações ou comentários adicionais da Axi, entre em contato: [email protected]

GlobeNewswire Distribution ID 1000966691

Adalvo obtient la première approbation générique de l’UE pour son stylo prérempli de liraglutide

SAN ĠWANN, Malte, 17 juin 2024 (GLOBE NEWSWIRE) — Adalvo annonce l’approbation par procédure décentralisée de son stylo prérempli de liraglutide, soit la toute première approbation générique dans l’UE.

En tant que version bio-équivalente du stylo prérempli Victoza®, indiqué pour le traitement du diabète de type 2, ce médicament peptidique a affiché des ventes mondiales supérieures à 4,8 milliards de dollars en 2023, comme le signale IQVIA.

Le développement réussi du liraglutide met en évidence la capacité d’Adalvo à proposer une gamme diversifiée et complète de traitements pour le diabète, intégrant à la fois des peptides complexes injectables et des traitements oraux à petites molécules.

L’engagement d’Adalvo à fournir un accès à des produits différenciés de haute qualité tout en en maîtrisant les enjeux de fabrication renforce sa position de leader reconnu au sein de l’industrie pharmaceutique.

Cliquez ici pour consulter la gamme de traitements pour le diabète conçue par Adalvo

Chez Adalvo, la notion de demi-mesure n’existe pas. À ce titre, les résultats sont toujours au rendez-vous. La mission de la Société est d’être plus rapide et plus performante que ses concurrents, à l’appui d’une équipe motivée au service de sa vision.

Adalvo s’engage à maintenir les normes d’excellence les plus strictes dans toutes ses activités et entend continuer à proposer des solutions de soins de santé novatrices qui apportent des changements positifs dans la vie des patients du monde entier.

À propos d’Adalvo

Adalvo est une entreprise pharmaceutique d’envergure mondiale et figure parmi les principales entreprises pharmaceutiques B2B d’Europe. Ses partenariats commerciaux sont actifs dans plus de 130 pays, à l’appui de plus de 140 partenaires commerciaux à l’échelle planétaire. L’objectif déclaré de l’entreprise vise l’amélioration de la vie des patients du monde entier au moyen d’un réseau de collaboration intelligent et d’un engagement à fournir des produits et services différenciés de la plus haute qualité à ses partenaires.

Adalvo est fière de sa capacité à accompagner ses partenaires dans la réalisation de leurs objectifs, qu’il s’agisse de relever leur chiffre d’affaires ou de conquérir de nouveaux marchés. Animée par un puissant désir d’apporter des résultats concrets à ses partenaires, Adalvo s’efforce sans relâche d’atteindre l’excellence dans toutes ses activités.

Grâce à sa culture axée sur les objectifs, l’entreprise s’engage à améliorer la vie des patients du monde entier. Son équipe de direction dynamique apporte une expérience et un savoir-faire industriels considérables ayant contribué à faire de l’entreprise un partenaire mondial fiable dans le secteur.

Contacts : Gabrielle Cassar, [email protected]

Une photo annexée à ce communiqué est disponible sur https://www.globenewswire.com/NewsRoom/AttachmentNg/e1e895aa-f689-4215-a1f8-25285851af9d

GlobeNewswire Distribution ID 1000966644

Adalvo obtém primeira aprovação genérica da UE para caneta pré-cheia com liraglutida

SAN ĠWANN, Malta, June 17, 2024 (GLOBE NEWSWIRE) — Adalvo anuncia a aprovação bem-sucedida do DCP para a caneta pré-cheia com liraglutida, marcando-a como a primeira aprovação genérica na UE.

Como uma versão bioequivalente da caneta pré-cheia Victoza®, indicada para o tratamento do diabetes tipo 2, este medicamento peptídico alcançou vendas globais superiores a US$ 4,8 bilhões em 2023, conforme divulgado pela IQVIA.

O desenvolvimento bem-sucedido do liraglutida destaca a capacidade da Adalvo de oferecer um portfólio diversificado e abrangente para diabetes, abrangendo tanto injetáveis de peptídeos complexos quanto tratamentos orais de moléculas pequenas.

O compromisso da Adalvo em fornecer acesso a produtos diferenciados de alta qualidade e, ao mesmo tempo, navegar pelas complexidades de fabricação, reforça a posição da empresa como líder confiável na indústria farmacêutica.

Clique aqui para ver o portfólio de diabetes da Adalvo

Na Adalvo, não há meias medidas – eles sempre atingem o objetivo. A sua missão é ser mais rápida e mais forte que os seus concorrentes, promovendo sua visão com uma equipe vencedora.

A Adalvo tem o compromisso de manter os mais altos padrões de excelência em todos os seus empreendimentos e espera continuar a fornecer soluções de saúde inovadoras que façam a diferença na vida dos pacientes em todo o mundo.

Sobre a Adalvo

A Adalvo é uma empresa farmacêutica global e uma das empresas farmacêuticas B2B líderes na Europa, com parcerias comerciais em mais de 130 países e mais de 140 parceiros comerciais em todo o mundo. O objetivo declarado da empresa é fazer a diferença para os pacientes em todo o mundo, motivado por nossa rede de colaboração inteligente e pelo compromisso de fornecer produtos e serviços diferenciados da mais alta qualidade aos nossos parceiros.

A Adalvo se orgulha de sua capacidade de ajudar os parceiros a atingir suas metas, seja para aumentar a receita ou entrar em novos mercados. Busca incansavelmente a excelência em todos os seus empreendimentos, movida por uma paixão profundamente enraizada por fazer a diferença para os parceiros.

A cultura orientada para o propósito da empresa está comprometida em melhorar a vida dos pacientes em todo o mundo. A equipe de liderança dinâmica da Adalvo traz uma experiência significativa e conhecimento do setor, o que ajudou a estabelecer a empresa como um parceiro global confiável no setor.

Contatos: Gabrielle Cassar, [email protected]

Uma foto que acompanha este anúncio está disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/e1e895aa-f689-4215-a1f8-25285851af9d

GlobeNewswire Distribution ID 1000966644

ADSK ANNOUNCEMENT: If You Have Suffered Losses in Autodesk, Inc. (NASDAQ: ADSK), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Autodesk, Inc. (NASDAQ: ADSK) between June 1, 2023 and April 16, 2024, both dates inclusive (the “Class Period”), shareholders who want to serve as lead plaintiff for the class must file their motions with the court by June 24, 2024.

If you purchased Autodesk securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

To join the Autodesk class action, go to https://rosenlegal.com/submit-form/?case_id=24019 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 24, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors.

Details of the caseAccording to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Autodesk, Inc. lacked adequate internal controls as a result of issues with its free cash flow and non-GAAP operating margin practices; and (2) as a result, defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.

What Now: You may be eligible to participate in the class action against Autodesk, Inc.. The deadline to file a motion to be appointed as lead plaintiff is June 24, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, go to https://rosenlegal.com/submit-form/?case_id=24019.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

GlobeNewswire Distribution ID 9154584

ALT ANNOUNCEMENT: If You Have Suffered Losses in Altimmune, Inc. (NASDAQ: ALT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the “Class Period”), shareholders who want to serve as lead plaintiff for the class must file their motions with the court by July 5, 2024.

If you purchased Altimmune securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

To join the Altimmune class action, go to https://rosenlegal.com/submit-form/?case_id=22535 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 5, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors.

Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Altimmune overstated the potential for its lead product candidate, pemvidutide, a glucagon-like peptide-1 (“GLP-1”), to stand out from competing GLP-1 agonists based on the drug’s efficacy and tolerability results observed in evaluating pemvidutide for the treatment of obesity (the “MOMENTUM Trial”); (2) accordingly, the MOMENTUM trial results were less significant to pemvidutide’s clinical, commercial, and competitive prospects than defendants had led investors to believe; (3) as a result of all the foregoing, defendants had overstated Altimmune’s prospects for finding a strategic partner to develop pemvidutide; and (4) as a result, Altimmune’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

GlobeNewswire Distribution ID 9154582

AKRO ANNOUNCEMENT: If You Have Suffered Losses in Akero Therapeutics, Inc. (NASDAQ: AKRO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusive (the “Class Period”), shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 12, 2024.

If you purchased Akero common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

To join the Akero class action, go to https://rosenlegal.com/submit-form/?case_id=24557 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 25, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors.

Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) approximately 20% of the patients enrolled in the SYMMETRY study, a trial that purportedly tested its  lead product candidate, efruxifermin (“EFX”) in patients with Non-alcoholic Steatohepatitis (“NASH”) induced cirrhosis, had cryptogenic cirrhosis and did not have definitive NASH at baseline; (2) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH; (3) the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints; (4) Akero had introduced a confounding factor into the SYMMETRY study’s design, materially influencing the study’s potential results and increasing the risks that the study would fail to meet its primary endpoint; (5) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not ruled out potential causes of each patient’s cirrhosis other than NASH; and (6) consequently, Akero had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood EFX would become a commercial treatment for NASH cirrhotics. When the true details entered the market, the lawsuit claims that investors suffered damages.

What Now: You may be eligible to participate in the class action against Akero Therapeutics. The deadline to file a motion to be appointed as lead plaintiff is August 12, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, go to https://rosenlegal.com/submit-form/?case_id=24557.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

GlobeNewswire Distribution ID 9154577

RBLX INVESTOR NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Roblox Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – RBLX

NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Roblox Corporation (NYSE: RBLX) between November 15, 2023 and May 8, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 12, 2024.

SO WHAT: If you purchased Roblox securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Roblox class action, go to https://rosenlegal.com/submit-form/?case_id=25991 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 12, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or created the false impression that they possessed reliable information pertaining to Roblox’s projected revenue outlook and anticipated bookings growth, due largely to expansions in Roblox’s available platforms, changes in Roblox’s digital technology (such as avatars), Roblox’s shared economy with content creators, and advertising revenue. In truth, Roblox knew each of those bookings and revenue sources were tenuous at best. In fact, Roblox faced difficulty converting daily average users (“DAUs”) into bookings and eventually blamed the very technology and platform growth it lauded as revolutionary and revenue-generating for this bookings problem. Defendants misled investors by providing the public with a materially flawed outlook for the relationship between DAU, bookings, and technology it lauded during its Investor Day and Earnings Call. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Roblox class action, go to https://rosenlegal.com/submit-form/?case_id=25991 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

GlobeNewswire Distribution ID 9154394